Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

  • There is currently no data for BMK

Share Premium Reduction

21 Mar 2023 17:33

RNS Number : 7702T
Benchmark Holdings PLC
21 March 2023
 

21 March 2023

 

Benchmark Holdings plc

("Benchmark" or the "Company")

Share Premium Reduction

21 March 2023

The Company announces that the cancellation of its share premium account (the "Capital Reduction"), which was approved by shareholders on 16 February 2023, is now effective. This follows the confirmation of the Capital Reduction by the High Court of England and Wales on 14 March 2023 and the registration of the Court order with the Registrar of Companies on 20 March 2023.

The Capital Reduction creates additional distributable reserves to the value of £394,235,072. The Company confirms that, following the Capital Reduction, the issued share capital of the Company remains at 739,277,469 ordinary shares of £0.001 each. The total number of voting rights in the Company also remains at 739,277,469.

Enquiries

 

For further information, please contact:

Benchmark Holdings plc

Tel: 0114 240 9939

Ivonne Cantu, Investor Relations

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith

MHP

Tel: 020 3128 8793 

Katie Hunt, Reg Hoare, Veronica Farah

benchmark@mhpgroup.com

 

About Benchmark

Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering mission-critical products and solutions in genetics, advanced nutrition and health which improve yield, growth and animal health and welfare. Through a global footprint in 26 countries and a broad portfolio of products and solutions, Benchmark addresses the major aquaculture species - salmon, shrimp, sea bass and bream, and tilapia, in all the aquaculture regions around the world.

Find out more at www.benchmarkplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUAOBROUUOUAR
Date   Source Headline
2nd Jul 20187:00 amRNSAppointment of Executive Director
29th Jun 20187:00 amRNSTotal Voting Rights
27th Jun 20184:36 pmRNSHolding(s) in Company
25th Jun 20184:01 pmRNSHolding(s) in Company
22nd Jun 20184:31 pmRNSHolding(s) in Company
22nd Jun 20187:00 amRNSDIRECTOR DEALINGS
19th Jun 20184:06 pmRNSUpdate on Joint Venture and Placing
19th Jun 20187:00 amRNSInterim Results
8th Jun 20187:00 amRNSJoint Venture, Placing and Trading Update
31st May 20187:00 amRNSTotal Voting Rights
8th May 20187:00 amRNSAppointment of Chairman
30th Apr 201812:23 pmRNSTotal Voting Rights
9th Apr 201811:14 amRNSHolding(s) in Company
5th Apr 20183:58 pmRNSHolding(s) in Company
3rd Apr 20187:00 amRNSTotal Voting Rights
27th Mar 20187:00 amRNSBenchmark hosts Capital Markets Day today
21st Mar 20187:00 amRNSBlock listing six monthly return
8th Mar 20181:37 pmRNSResult of AGM
7th Feb 20189:05 amRNSDirector Dealings
31st Jan 20187:00 amRNSBoard Succession
31st Jan 20187:00 amRNSTotal Voting Rights
25th Jan 201811:54 amRNSDirector Share Options
24th Jan 20183:17 pmRNSHolding(s) in Company
24th Jan 20181:01 pmRNSDirector Dealings
24th Jan 20187:00 amRNSPosting of Annual Report & Notice of AGM
23rd Jan 20187:08 amRNSFinal Results
19th Jan 20184:40 pmRNSSecond Price Monitoring Extn
19th Jan 20184:35 pmRNSPrice Monitoring Extension
5th Jan 20184:19 pmRNSHolding(s) in Company
4th Jan 20184:41 pmRNSSecond Price Monitoring Extn
4th Jan 20184:35 pmRNSPrice Monitoring Extension
12th Dec 20177:00 amRNSCommercial scale field trial of sea lice treatment
7th Dec 20177:00 amRNSBenchmark participates in gene editing research
5th Dec 20177:00 amRNSTrading Update and Notice of Results
8th Nov 20177:00 amRNSDevelopment of disease-resistant shrimp
6th Nov 201712:20 pmRNSReplacement: Directorate Change
6th Nov 20177:00 amRNSDirectorate Change
30th Oct 20177:00 amRNSLand-based Broodstock Facility Reaches Milestone
17th Oct 20177:00 amRNSNew Vaccine Facility Delivers First Production
10th Oct 20172:41 pmRNSHolding(s) in Company
21st Sep 20177:00 amRNSBlock Listing Six Monthly Return
8th Sep 20177:00 amRNSTrading Update
22nd Aug 20177:00 amRNSRenewal of Sales and Marketing Agreement
16th Aug 20177:00 amRNSLaunch of breakthrough purification system
28th Jul 20172:57 pmRNSDirector leave of absence
27th Jun 20177:02 amRNSHalf-year Report
19th Jun 20173:00 pmRNSNotice of Results
25th May 20177:00 amRNSTrading Update and Notice of Results
2nd May 20177:00 amRNSTotal Voting Rights
26th Apr 201710:54 amRNSDirector Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.